NOTES
TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(UNAUDITED)
|
1.
|
Organization
and Business Overview
|
General
–
BioTime, Inc. (“BioTime” or the “Company”) is a clinical-stage, biotechnology company targeting
degenerative diseases. BioTime’s programs are based on two proprietary core technology platforms: cell replacement and cell/drug
delivery. With the cell replacement platform, BioTime is producing new cells and tissues with its pluripotent and progenitor cell
technologies. These cells and tissues are developed to replace those that are either rendered dysfunctional or lost due to degenerative
diseases or injuries. BioTime’s cell/drug delivery programs are based upon its proprietary HyStem
®
cell and
drug delivery matrix technology. HyStem
®
was designed to provide for the transfer, retention, and/or engraftment
of cell replacement therapies and to act as a device for localized drug delivery.
BioTime’s
lead cell replacement clinical product is OpRegen
®
, a retinal pigmented epithelium (RPE) cell replacement therapy,
which is in a Phase I/IIa multicenter trial for the treatment of late-stage, dry age-related macular degeneration (dry-AMD). There
are currently no FDA-approved therapies for dry-AMD, which accounts for approximately 90% of all age-related macular degeneration
cases, and is the leading cause of blindness in people over the age of 60.
BioTime’s
lead cell delivery clinical product, based on its proprietary HyStem
®
technology, is Renevia
®
, a
potential treatment for facial lipoatrophy. “Lipoatrophy” means the loss of fat tissue, which can be caused by several
factors, including trauma, aging, or drug side effects, such as those that cause HIV-associated lipoatrophy. BioTime is also developing
HyStem® for the sustained delivery of therapeutic drugs and targeted cells to specific areas of the body.
BioTime
is also enabling early-stage programs in other new technologies through its own research programs as well as through other subsidiaries
or affiliates.
In
2017, BioTime formed AgeX Therapeutics, Inc. (“AgeX”) to continue development of initial discovery and preclinical
programs with a focus on utilizing brown adipose tissue (“brown fat”) in targeting diabetes, obesity, and heart disease;
and induced tissue regeneration (“iTR”) in utilizing the human body’s own abilities to scarlessly regenerate
tissues damaged from age or trauma
. AgeX may also pursue other early-stage preclinical programs.
On
August 17, 2017, AgeX completed an asset acquisition and stock sale pursuant to which it received certain assets from BioTime
for use in its research and development programs and raised $10.0 million in cash from investors to finance its operations.
As
discussed in Note 3,
on August 30, 2018, BioTime
entered into a Stock Purchase Agreement (the “Purchase Agreement”) with Juvenescence Limited (“Juvenescence”)
and AgeX pursuant to which BioTime sold 14,400,000 shares of its shares of AgeX common stock to Juvenescence for $3.00 per share
(the “Juvenescence Transaction”). Prior to the Juvenescence Transaction, Juvenescence owned 5.6% of AgeX’s issued
and outstanding common stock. Upon completion of the Juvenescence Transaction, BioTime’s ownership in AgeX decreased from
80.4% to 40.2% of AgeX’s issued and outstanding shares of common stock, and Juvenescence’s ownership in AgeX increased
from 5.6% to 45.8% of AgeX’s issued and outstanding shares of common stock.
As a result
of the Juvenescence Transaction, as of August 30, 2018, BioTime owned less than 50% of AgeX’s outstanding common stock and
experienced a loss of control of AgeX in accordance with accounting principles generally accepted in the United States (“GAAP”).
Under GAAP, loss of control of a subsidiary is deemed to have occurred when, among other things, a parent company owns less than
a majority of the outstanding common stock of the subsidiary, lacks a controlling financial interest in the subsidiary, and is
unable to unilaterally control the subsidiary through other means such as having the ability or being able to obtain the ability
to elect a majority of the subsidiary’s Board of Directors. BioTime determined that all of these loss of control factors
were present with respect to AgeX on August 30, 2018. Accordingly, BioTime has deconsolidated AgeX’s consolidated financial
statements and consolidated results of operations from BioTime, effective August 30, 2018 (the “AgeX Deconsolidation”),
in accordance with Accounting Standards Codification, or ASC 810-10-40-4(c),
Consolidation
. Since August 30, 2018, BioTime
has accounted for the AgeX common stock it holds using the equity method of accounting at fair value (see Note 5).
As
discussed in Note 16, on November 5, 2018, AgeX filed Amendment No. 4 to its Registration Statement on Form 10 with the Securities
and Exchange Commission (“SEC”) in connection with BioTime’s planned distribution of shares of AgeX common stock
owned by BioTime to holders of BioTime common shares, on a pro rata basis (the “AgeX Distribution”). If the AgeX Distribution
is completed, BioTime shareholders of record on November 16, 2018 will receive one share of AgeX common stock for every 10 BioTime
common shares they own on November 28, 2018, the expected “Distribution Date”.
BioTime
also has significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. (“Asterias”)
and OncoCyte Corporation (“OncoCyte”), which BioTime founded and, until recently, were majority-owned and consolidated
subsidiaries. Asterias (NYSE American: AST) is presently focused on advancing three clinical-stage programs that have the potential
to address areas of very high unmet medical needs in the fields of neurology (spinal cord injury) and oncology (Acute Myeloid
Leukemia and lung cancer). OncoCyte (NYSE American: OCX) is developing confirmatory diagnostic tests for lung cancer utilizing
novel liquid biopsy technology. See Note 16 for the definitive merger agreement entered into by BioTime and Asterias on November
7, 2018, for BioTime to acquire the remaining ownership interest in Asterias (see Note 7).
Beginning
on February 17, 2017, BioTime deconsolidated OncoCyte’s financial statements and results of operations from BioTime (the
“OncoCyte Deconsolidation”) (see Notes 4 and 6).
Beginning
on May 13, 2016, BioTime deconsolidated Asterias’ financial statements and results of operations from BioTime (the “Asterias
Deconsolidation”) (see Notes 7 and 16).
|
2.
|
Basis
of Presentation, Liquidity and Summary of Significant Accounting Policies
|
The
unaudited condensed consolidated interim financial statements presented herein, and discussed below, have been prepared in accordance
with GAAP for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC.
In accordance with those rules and regulations certain information and footnote disclosures normally included in comprehensive
consolidated financial statements have been condensed or omitted. The condensed consolidated balance sheet as of December 31,
2017 was derived from the audited consolidated financial statements at that date, but does not include all the information and
footnotes required by GAAP. These condensed consolidated interim financial statements should be read in conjunction with the audited
consolidated financial statements and notes thereto included in BioTime’s Annual Report on Form 10-K, as amended, for the
year ended December 31, 2017,
the audited annual consolidated financial statements of AgeX
for the year ended December 31, 2017 and the AgeX unaudited condensed consolidated interim financial statements as of, and for
the nine months ended September 30, 2018 included in Amendment No. 4 to AgeX’s Registration Statement on Form 10 filed on
November 5, 2018 with the SEC (see Note 16)
.
The
accompanying condensed consolidated interim financial statements, in the opinion of management, include all adjustments, consisting
only of normal recurring adjustments, necessary for a fair presentation of BioTime’s financial condition and results of
operations. The condensed consolidated results of operations are not necessarily indicative of the results to be expected for
any other interim period or for the entire year.
Principles
of consolidation –
BioTime’s condensed consolidated interim financial statements present the operating results
of all of its wholly-owned and majority-owned subsidiaries that it consolidates as required under GAAP. All material intercompany
accounts and transactions have been eliminated in consolidation. BioTime consolidated Cell Cure Neurosciences, Ltd (“Cell
Cure”), OrthoCyte Corporation (“OrthoCyte”), ES Cell International, Pte Ltd (“ESI”) and BioTime
Asia, Limited (“BioTime Asia”), as BioTime has the ability to control their operating and financial decisions and
policies through its stock ownership or representation on the board of directors, and the noncontrolling interest is reflected
as a separate element of shareholders’ equity on BioTime’s condensed consolidated balance sheets.
BioTime’s
consolidated balance sheet at December 31, 2017, as reported, includes AgeX’s consolidated assets and liabilities, after
intercompany eliminations. However, AgeX’s consolidated assets and liabilities are not included in BioTime’s unaudited
condensed consolidated balance sheet at September 30, 2018, due to the deconsolidation of AgeX on August 30, 2018.
AgeX’s
consolidated financial statements and consolidated results of operations
include its majority owned and consolidated subsidiaries,
including ReCyte Therapeutics, Inc. (“ReCyte”), LifeMap Sciences, Inc. (“LifeMap Sciences”) and LifeMap
Sciences, Ltd.
BioTime’s
unaudited consolidated statements of operations for the three and nine months ended September 30, 2018 include AgeX’s consolidated
results for the period through August 29, 2018, the day immediately preceding the AgeX Deconsolidation. For the three and nine
months ended September 30, 2017, BioTime’s unaudited consolidated results include AgeX’s consolidated results for
the full periods presented. As a result of the AgeX Deconsolidation, beginning on August 30, 2018 (a) AgeX’s consolidated
financial statements and consolidated results are no longer a part of BioTime’s condensed consolidated interim financial
statements and results, and (b) the fair value of AgeX common stock held by BioTime is now reflected on BioTime’s condensed
consolidated balance sheet and the changes in the fair value of those shares during the applicable accounting period are reflected
as gains or losses in BioTime’s condensed consolidated statements of operations. Since AgeX’s common stock is not
publicly traded, fair value is estimated (see Note 5).
Beginning
on February 17, 2017 and May 13, 2016, respectively, OncoCyte and Asterias financial statements and results are no longer a part
of BioTime’s condensed consolidated interim financial statements and results. The market value of OncoCyte and Asterias
common stock held by BioTime is now reflected on BioTime’s condensed consolidated balance sheet and the changes in the market
value of those shares during the applicable accounting period are reflected as gains or losses in BioTime’s condensed consolidated
statements of operations, allowing BioTime shareholders to evaluate the value of the respective OncoCyte and Asterias’ portion
of BioTime’s business.
OncoCyte’s
results are not included in BioTime’s condensed consolidated statements of operations for the three and nine months ended
September 30, 2018, and the three months ended September 30, 2017. BioTime’s condensed consolidated statements of operations
for the nine months ended September 30, 2017 include OncoCyte’s results for the period from January 1, 2017 through February
16, 2017, the day immediately preceding the OncoCyte Deconsolidation.
Liquidity
–
Since inception, BioTime has incurred significant operating losses and has funded its operations primarily through
the issuance of equity securities, sale of common stock of a former subsidiary, payments from research grants, royalties from
product sales and sales of research products and services. At September 30, 2018, BioTime had an accumulated deficit of $216.9
million, working capital of $32.4 million and shareholders’ equity of $169.6 million. BioTime has evaluated its projected
cash flows and believes that its $32.2 million of cash, cash equivalents, receivable from Juvenescence (Notes 3 and 16) and marketable
equity securities at September 30, 2018, provide
sufficient cash, cash equivalents and liquidity
to carry out BioTime’s current operations through at least twelve months from the issuance date of the
condensed
consolidated interim financial statements included in this Report. BioTime also holds shares
of Asterias and OncoCyte common stock with a combined market value of $65.0 million at
September
30,
2018.
Although BioTime has no present plans to liquidate its holdings of Asterias or OncoCyte shares, if BioTime needs
near term working capital or liquidity to supplement its cash and cash equivalents for its operations, BioTime may sell some,
or all, of its Asterias or OncoCyte shares, as necessary.
If
the AgeX Distribution is completed, AgeX will become a public company and BioTime will continue to hold a minor interest in AgeX
common stock that may be a source of additional liquidity to BioTime as a marketable equity security. The AgeX Distribution is
subject to numerous conditions, including the SEC declaring AgeX’s Registration Statement on Form 10 effective. There can
be no assurance that the AgeX Distribution will be completed (see Note 16).
If
the Juvenescence Promissory Note discussed in Note 3 is converted to Juvenescence common stock prior to its maturity date, the
Juvenescence common stock may be a marketable security that BioTime may use to supplement its liquidity, as needed. If the Promissory
Note is not converted, it is payable in cash, plus accrued interest, at maturity (see Note 3). There can be no assurance that
the Promissory Note will be converted prior to maturity.
BioTime’s
projected cash flows are subject to various risks and uncertainties, and the unavailability or inadequacy of financing to meet
future capital needs could force it to modify, curtail, delay, or suspend some or all aspects of its planned operations. BioTime’s
determination as to when it will seek new financing and the amount of financing that it will need will be based on its evaluation
of the progress it makes in its research and development programs, any changes to the scope and focus of those programs, and projection
of future costs, revenues, and rates of expenditure. For example, clinical trials being conducted for its OpRegen
®
program will be funded in part with funds from grants and not from cash on hand. If BioTime were to lose grant funding or is unable
to continue to provide working capital to the OpRegen
®
program, it may be required to delay, postpone, or cancel
the clinical trials or limit the number of clinical trial sites, unless BioTime is able to obtain adequate financing from another
source that could be used for the clinical trials.
As
discussed on Note 16, on November 7, 2018, BioTime entered into a definitive merger agreement with Asterias to acquire the
remaining ownership interest in Asterias (see Note 7). The acquisition is expected to close in the first quarter of 2019,
subject to approval by the shareholders of each of BioTime and Asterias and the satisfaction of other customary closing
conditions. As of September 30, 2018, BioTime owns approximately 39% of the issued and outstanding shares of Asterias
common stock.
If
the merger is completed, Asterias will cease to exist as a public company and this marketable security will not be a source
of possible liquidity to BioTime, BioTime will consolidate Asterias’ operations and results with its operations and
consolidated results beginning on the consummation of the merger. If the merger is completed, BioTime expects to incur
significant costs in connection with consummating the merger and integrating the operations of Asterias. BioTime may incur
additional costs to maintain employee morale and to retain key employees. BioTime will also incur significant fees and
expenses relating to legal, accounting and other transaction fees and other costs associated with the merger. Some of these
costs are payable regardless of whether the merger is completed. Moreover, under specified circumstances, the merger
agreement requires either party to pay the other a termination fee of $2.0 million if the merger is not consummated
or, under specified circumstances, an expense reimbursement of $1.5 million which will be credited against the
termination fee.
The unavailability or inadequacy of financing to meet future
capital needs could force BioTime to further modify, curtail, delay, or suspend some or all aspects of
planned operations.
BioTime
cannot assure that adequate future financing will be available on favorable terms, if at all, when needed.
Sales
of additional equity securities by BioTime or its subsidiaries could result in the dilution of the interests of present shareholders.
As
discussed in Note 14, t
he planned AgeX Distribution
will be a taxable event to BioTime. The amount of income tax obligation, if any, that BioTime may incur in connection with the
AgeX Distribution is not estimable at this time since the tax obligation depends on numerous factors and contingencies including,
but not limited to, the completion of the AgeX Distribution, the amount and availability of U.S. net operating losses generated
by BioTime to offset any taxable gain as a result of the AgeX Distribution, and the value of AgeX common stock on the distribution
date.
Equity
method accounting for AgeX, OncoCyte and Asterias, at fair value –
BioTime uses
the equity method of accounting when it has the ability to exercise significant influence, but not control, as determined in accordance
with GAAP, over the operating and financial policies of a company. For equity method assets which BioTime has elected to measure
at fair value, unrealized gains and losses are reported in the condensed consolidated statements of operations in other income
and expenses, net.
As
further discussed in Notes 5, 6 and 7, BioTime has elected to account for its AgeX, OncoCyte and Asterias shares at fair value
using the equity method of accounting because beginning on August 30, 2018, February 17, 2017 and May 13, 2016, the respective
dates on which BioTime deconsolidated AgeX, OncoCyte and Asterias (see Note 16), BioTime has not had control of AgeX, OncoCyte
and Asterias, as defined by GAAP, but continues to exercise significant influence over those companies. Under the fair value method,
BioTime’s value in shares of common stock it holds in OncoCyte and Asterias is marked to market at each balance sheet date
using the closing prices of OncoCyte and Asterias common stock on the NYSE American multiplied by the number of shares of OncoCyte
and Asterias held by BioTime, with changes in the fair value of the OncoCyte and Asterias shares included in other income and
expenses, net, in the condensed consolidated statements of operations. The OncoCyte and Asterias shares are considered level 1
assets as defined by ASC 820,
Fair Value Measurements and Disclosures
.
BioTime
accounts for the AgeX shares it continues to hold in a manner similar to the accounting for Asterias and OncoCyte shares held,
except the fair value of the AgeX shares is estimated by BioTime at each reporting period because AgeX common stock is not publicly
traded. Accordingly, the AgeX shares are considered level 2 assets as defined by ASC 820 (see Note 5 for a discussion of factors
used to determine the fair value of AgeX common stock beginning on August 30, 2018, the date of the AgeX Deconsolidation).
Marketable
equity securities
– BioTime accounts for the shares it holds in foreign equity securities as marketable equity in accordance
with ASC 320-10-25,
Investments – Debt and Equity Securities
, as amended by Accounting Standards Update (“ASU”)
2016-01,
Financial Instruments–Overall: Recognition and Measurement of Financial Assets and Financial Liabilities
,
further discussed below, as the shares have a readily determinable fair value quoted on the Tel Aviv Stock Exchange (“TASE”)
(under trading symbol “HDST”) where share prices are denominated in New Israeli Shekels (NIS). These securities are
held principally to meet future working capital needs. The securities are measured at fair value and reported as current assets
on the condensed consolidated balance sheets based on the closing trading price of the security as of the date being presented.
Beginning on January 1, 2018, with the adoption of ASU 2016-01 discussed below, these securities are now called “marketable
equity securities” and unrealized holding gains and losses on these securities, including changes in foreign currency exchange
rates, are reported in the condensed consolidated statements of operations in other income and expenses, net. Prior to January
1, 2018 and the adoption of ASU 2016-01, these securities were called “available-for-sale securities” and unrealized
holding gains and losses, including changes in foreign currency exchange rates, were reported in other comprehensive income or
loss, net of tax, and were a component of the accumulated other comprehensive income or loss on the consolidated balance sheet.
Realized gains and losses, and declines in value judged to be other-than-temporary related to marketable equity securities, are
included in other income and expenses, net, in the condensed consolidated statements of operations.
On
January 1, 2018, in accordance with the adoption of ASU 2016-01, BioTime recorded a cumulative-effect adjustment for these available-for-sale-securities
to reclassify the unrealized gain of $328,000 included in consolidated accumulated other comprehensive income to the consolidated
accumulated deficit balance. For the three and nine months ended September 30, 2018, BioTime recorded an unrealized gain of $23,000
and $635,000, respectively, included in other income and expenses, net, due to the increase in fair market value of the marketable
equity securities from December 31, 2017 to September 30, 2018.
Basic
and diluted net income (loss) per share attributable to common shareholders
– Basic earnings per share is calculated
by dividing net income or loss attributable to BioTime common shareholders by the weighted average number of common shares outstanding,
net of unvested restricted stock or restricted stock units, subject to repurchase by BioTime, if any, during the period. Diluted
earnings per share is calculated by dividing the net income or loss attributable to BioTime common shareholders by the weighted
average number of common shares outstanding, adjusted for the effects of potentially dilutive common shares issuable under outstanding
stock options and warrants, using the treasury-stock method, convertible preferred stock, if any, using the if-converted method,
and treasury stock held by subsidiaries, if any.
The
primary components of the weighted average number of potentially dilutive common shares used to compute diluted net income per
common share for the three months ended September 30, 2018 were approximately 95,000 outstanding stock options and restricted
stock units. For the nine months ended
September
30, 2018, there were no potentially dilutive common share equivalents due to the net loss
reported for the period presented.
The
primary components of the weighted average number of potentially dilutive common shares used to compute diluted net income per
common share for the three months ended September 30, 2017 were approximately 10,000 outstanding stock options and restricted
stock units.
The primary components of weighted
average shares of potentially dilutive common shares used to compute diluted net income per common share for the nine months ended
September 30, 2017 were
109
,000 shares of treasury stock and
26
,000
restricted stock units and outstanding stock options (see Note 13).
The
following common share equivalents were excluded from the computation of diluted net income (loss) per common share for the periods
presented because including them would have been antidilutive (in thousands):
|
|
Three Months Ended
September 30,
(unaudited)
|
|
|
Nine Months Ended
September 30,
(unaudited)
|
|
|
|
2018
|
|
|
2017
|
|
|
2018
|
|
|
2017
|
|
Stock options
|
|
|
9,742
|
|
|
|
7,915
|
|
|
|
9,301
|
|
|
|
7,871
|
|
Warrants
(1)
|
|
|
8,795
|
|
|
|
9,395
|
|
|
|
9,138
|
|
|
|
9,395
|
|
Restricted stock units
|
|
|
83
|
|
|
|
-
|
|
|
|
286
|
|
|
|
-
|
|
(1)
The
warrants expired on October 1, 2018 (see Note 16).
Recently
adopted accounting pronouncements
Adoption
of ASU 2016-18
,
Statement of Cash Flows (Topic 230).
On January 1, 2018,
BioTime adopted Financial Accounting Standards Board (“FASB”) ASU 2016-18,
Statement of Cash Flows (Topic 230):
Restricted Cash
, which requires that the statement of cash flows explain the change during the period in the total of cash,
cash equivalents and restricted cash, and that restricted cash be included with cash and cash equivalents when reconciling the
beginning-of-period and end-of-period total amounts shown on the condensed consolidated statements of cash flows. The adoption
of ASU 2016-18 did not have a material effect on BioTime’s condensed consolidated financial statements. However, prior period
restricted cash balances included in prepaid expenses and other current assets, and in deposits and other long-term assets, on
the condensed consolidated balance sheets was added to the beginning-of-period and end-of-period total consolidated cash and cash
equivalents in the condensed consolidated statements of cash flows to conform to the current presentation shown below.
The
following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated
balance sheet dates that comprise the total of the same such amounts shown in the condensed consolidated statements of cash flows
for all periods presented herein and effected by the adoption of ASU 2016-18 (in thousands):
|
|
September 30,
2018
(unaudited)
|
|
|
December 31,
2017
|
|
|
September 30,
2017
(unaudited)
|
|
|
December 31,
2016
|
|
Cash and cash equivalents
|
|
$
|
19,467
|
|
|
$
|
36,838
|
|
|
$
|
16,662
|
|
|
$
|
22,088
|
|
Restricted cash included in prepaid expenses and other current assets (see Note 15)
|
|
|
424
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Restricted cash included in deposits and other long-term assets (see Note 15)
|
|
|
396
|
|
|
|
847
|
|
|
|
847
|
|
|
|
847
|
|
Total cash, cash equivalents, and restricted cash as shown in the condensed consolidated statements of cash flows
|
|
$
|
20,287
|
|
|
$
|
37,685
|
|
|
$
|
17,509
|
|
|
$
|
22,935
|
|
Adoption
of ASU 2014-09
, Revenues from Contracts with Customers (Topic 606).
In May 2014,
the FASB issued ASU 2014-09 (“Topic 606”)
Revenue from Contracts with Customers
which supersedes the revenue
recognition requirements in Topic 605
Revenue Recognition
(“Topic 605”). Topic 606 describes principles an
entity must apply to measure and recognize revenue and the related cash flows, using the following five steps: (i) identify the
contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price;
(iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) the
entity satisfies a performance obligation. Topic 606 core principle is that it requires entities to recognize revenue when control
of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity
expects to be entitled to in exchange for those goods or services.
BioTime
adopted Topic 606 as of January 1, 2018 using the modified retrospective transition method applied to those contracts which were
not completed as of the adoption date. Results for reporting periods beginning on January 1, 2018 and thereafter are presented
under Topic 606, while prior period amounts are not adjusted and continue to be reported in accordance with BioTime’s historical
revenue recognition accounting under Topic 605.
On
January 1, 2018, the adoption and application of Topic 606 resulted in an immaterial cumulative effect adjustment to BioTime’s
beginning consolidated accumulated deficit balance. In the applicable paragraphs below, BioTime has summarized its revenue recognition
policies for its various revenue sources in accordance with Topic 606.
Revenue
Recognition by Source and Geography
. Revenues are recognized when control of the promised goods or services is transferred
to customers, or in the case of governmental entities funding a grant, when allowable expenses are incurred, in an amount that
reflects the consideration BioTime or a subsidiary, depending on which company has the customer or the grant, expects to be entitled
to in exchange for those goods or services. See further discussion under
Grant Revenues
below.
The
following table presents BioTime’s unaudited consolidated revenues disaggregated by source (in thousands).
|
|
Three Months Ended
September 30,
|
|
|
Nine Months Ended
September 30,
|
|
|
|
2018
|
|
|
2017
(1)
|
|
|
2018
|
|
|
2017
(1)
|
|
REVENUES:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Grant revenue
|
|
$
|
718
|
|
|
$
|
1,225
|
|
|
$
|
2,985
|
|
|
$
|
1,236
|
|
Royalties from product sales and license fees
|
|
|
85
|
|
|
|
86
|
|
|
|
312
|
|
|
|
277
|
|
Subscription and advertisement revenues
(2)
|
|
|
119
|
|
|
|
376
|
|
|
|
691
|
|
|
|
940
|
|
Sale of research products and services
|
|
|
60
|
|
|
|
1
|
|
|
|
242
|
|
|
|
6
|
|
Total revenues
|
|
$
|
982
|
|
|
|
1,688
|
|
|
|
4,230
|
|
|
|
2,459
|
|
(1)
Amounts
recognized prior to adoption of Topic 606 have not been adjusted under the Topic 606 modified retrospective transition method.
(2)
These
revenues were generated by LifeMap Sciences, which is now a subsidiary of AgeX. As a result of the AgeX Deconsolidation BioTime
does not expect to recognize subscription and advertisement revenues during subsequent accounting periods.
The
following table presents unaudited consolidated revenues, disaggregated by geography, based on the billing addresses of customers,
or in the case of grant revenues based on where the governmental entities that fund the grant are located. Amounts shown are in
unaudited and in thousands. See further discussion under
Grant Revenues
below.
|
|
Three Months Ended
September 30,
|
|
|
Nine Months Ended
September 30,
|
|
|
|
2018
|
|
|
2017
(1)
|
|
|
2018
|
|
|
2017
(1)
|
|
REVENUES:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
United States
|
|
$
|
403
|
|
|
$
|
209
|
|
|
$
|
1,541
|
|
|
$
|
569
|
|
Foreign
(2)
|
|
|
579
|
|
|
|
1,479
|
|
|
|
2,689
|
|
|
|
1,890
|
|
Total revenues
|
|
$
|
982
|
|
|
$
|
1,688
|
|
|
$
|
4,230
|
|
|
$
|
2,459
|
|
(1)
Amounts
recognized prior to adoption of Topic 606 have not been adjusted under the Topic 606 modified retrospective transition method.
(2)
Foreign
revenues are primarily generated from grants in Israel.
Research
and development contracts with customers.
In its agreements with customers, BioTime’s performance obligations of research
and development are completed as services are performed and control passes to the customer, and accordingly revenues are recognized
over time. BioTime generally receives a fee at the inception of an agreement, with variable fees, if any, tied to certain milestones,
if achieved. BioTime estimates this variable consideration using a single most likely amount. Based on historical experience,
there has been no variable consideration related to milestones included in the transaction price due to the significant uncertainty
of achieving contract milestones and milestones not being met. If a milestone is met, subsequent changes in the single most likely
amount may produce a different variable consideration, and BioTime will allocate any subsequent changes in the transaction price
on the same basis as at contract inception. Amounts allocated to a satisfied performance obligation will be recognized as revenue
in the period in which the transaction price changes with respect to variable consideration, which could result in a reduction
of revenue. Contracts of this kind are typically for a term greater than one year. For each of the three and nine months ended
September 30, 2018 and 2017, BioTime recognized $77,000 and $231,000 for such services included in the consolidated royalties
from product sales and license fees, respectively. The aggregate amount of the transaction price, excluding payments related to
any milestones, allocated to performance obligations that are unsatisfied, or partially unsatisfied, as of September 30, 2018
was $77,000, included in deferred revenues in the consolidated balance sheets. BioTime expects to recognize revenue of $77,000
through the year ending December 31, 2018. As of September 30, 2018, BioTime had not met any milestones that would require adjustment
of the transaction price.
Royalties
from product sales and license fees.
BioTime’s performance obligations in agreements with certain customers is to provide
a license to allow customers to make, import and sell company licensed products or methods for pre-clinical studies and commercial
use. Customers pay a combination of a license issue fee paid up front and a sales-based royalty, if any, in some cases with yearly
minimums. The transaction price is deemed to be the license issue fee stated in the contract. The license offered by BioTime is
a functional license with significant standalone functionality and provides customers with the right to use BioTime’s intellectual
property. This allows BioTime to recognize revenue on the license issue fee at a point in time at the beginning of the contract,
which is when the customer begins to have use of the license. Variable consideration related to sales-based royalties is recognized
only when (or as) the later of the following events occurs: (a) a sale or usage occurs, or (b) the performance obligation to which
some, or all, of the sales-based or usage-based royalty has been allocated has been satisfied or partially satisfied. Due to the
contract termination clauses, BioTime does not expect to receive all of the minimum royalty payments throughout the term of the
agreements. Therefore, BioTime fully constrains recognition of the minimum royalty payments as revenues until its customers are
obligated to pay, which is generally within 60 days prior to beginning of each year the minimum royalty payments are due. For
the three and nine months ended September 30, 2018 and 2017, royalty revenues were immaterial.
Sale
of research products and services.
Revenues from the sale of research products and services shown in the table above are primarily
derived from the sale of hydrogels and stem cell products for research use and are recognized when earned. Revenues from the sale
of hydrogels and stem cell products were immaterial for all periods presented.
Subscription
and advertisement revenues
. LifeMap Sciences, a direct majority-owned subsidiary of AgeX, sells subscription-based products
,
including research databases and software tools,
for b
iomedical, gene, disease, and
stem cell research.
LifeMap Sciences sells these subscriptions primarily through the internet to biotech and pharmaceutical
companies worldwide. LifeMap Sciences’ principal subscription product is the GeneCards
®
Suite, which includes
the GeneCards
®
human gene database, and the MalaCards™ human disease database.
LifeMap
Sciences’ performance obligations for subscriptions include a license of intellectual property related to its genetic information
packages and premium genetic information tools. These licenses are deemed functional licenses that provide customers with a “right
to access” to LifeMap Sciences’ intellectual property during the subscription period and, accordingly, revenue is
recognized over a period of time, which is generally the subscription period. Payments are typically received at the beginning
of a subscription period and revenue is recognized according to the type of subscription sold.
For
subscription contracts in which the subscription term commences before a payment is due, LifeMap Sciences records an accounts
receivable as the subscription is earned over time and bills the customer according to the contract terms. LifeMap Sciences continuously
monitors collections and payments from customers and maintains a provision for estimated credit losses and uncollectible accounts
based upon its historical experience and any specific customer collection issues that have been identified. Amounts determined
to be uncollectible are written off against the allowance for doubtful accounts. LifeMap Sciences has not historically provided
significant discounts, credits, concessions, or other incentives from the stated price in the contract as the prices are offered
on a fixed fee basis for the type of subscription package being purchased. LifeMap Sciences may issue refunds only if the packages
cease to be available for reasons beyond its control. In such an event, the customer will get a refund on a pro-rata basis. Using
the most likely amount method for estimating refunds under Topic 606, including historical experience, LifeMap Sciences determined
that the single most likely amount of variable consideration for refunds is immaterial as LifeMap Sciences does not expect to
pay any refunds. Both the customer and LifeMap Sciences expect the subscription packages to be available during the entire subscription
period, and LifeMap Sciences has not experienced any significant issues with the availability of the product and has not issued
any material refunds.
LifeMap
Sciences performance obligations for advertising are overall advertising services and represent a series of distinct services.
Contracts are typically less than a year in duration and the fees charged may include a combination of fixed and variable fees
with the variable fees tied to click throughs to the customer’s products on their website. LifeMap Sciences allocates the
variable consideration to each month the click through services occur and allocates the annual fee to the performance obligation
period of the initial term of the contract because those amounts correspond to the value provided to the customer each month.
For click-through advertising services, at the time the variable compensation is known and determinable, the service has been
rendered. Revenue is recognized at that time. The annual fee is recognized over the initial subscription period because this is
a service and the customer simultaneously receives and consumes the benefit of LifeMap Sciences’ performance.
LifeMap
Sciences deferred subscription revenues primarily represent subscriptions for which cash payment has been received for the subscription
term, but the subscription term has not been completed as of the balance sheet date reported. No revenues from subscription and
advertisement products have been recorded since August 29, 2018 because of the AgeX Deconsolidation. The LifeMap Sciences revenues
shown for the three and nine months ended September 30, 2018 are for revenues earned through August 29, 2018, the date immediately
preceding the AgeX Deconsolidation. As a result of the AgeX Deconsolidation, BioTime does not expect to earn subscription and
advertising revenues in subsequent accounting periods.
For
the three months ended September 30, 2018 and 2017, LifeMap Sciences recognized $119,000 and $376,000 in subscription and advertisement
revenues. For the nine months ended September 30, 2018 and 2017, LifeMap Sciences recognized $691,000 and $940,000 in subscription
and advertisement revenues. As of September 30, 2018, there were no deferred revenues related to LifeMap Sciences included in
the condensed consolidated balance sheets due to the AgeX Deconsolidation on August 30, 2018.
LifeMap
Sciences has licensed from a third party the databases it commercializes and has a contractual obligation to pay royalties to
the licensor on subscriptions sold. These costs are included in cost of sales on the condensed consolidated statements of operations
when the cash is received and the royalty obligation is incurred as the royalty payments do not qualify for capitalization of
costs to fulfill a contract under ASC 340-40,
Other Assets and Deferred Costs – Contracts with Customers
.
Grant
revenues
. In applying the provisions of Topic 606, BioTime has determined that government grants are out of the scope of Topic
606 because the government entities do not meet the definition of a “customer”, as defined by Topic 606, as there
is not considered to be a transfer of control of good or services to the government entities funding the grant. BioTime has, and
will continue to, account for grants received to perform research and development services in accordance with ASC 730-20,
Research
and Development Arrangements
, which requires an assessment, at the inception of the grant, of whether the grant is a liability
or a contract to perform research and development services for others. If BioTime or a subsidiary receiving the grant is obligated
to repay the grant funds to the grantor regardless of the outcome of the research and development activities, then BioTime is
required to estimate and recognize that liability. Alternatively, if BioTime or a subsidiary receiving the grant is not required
to repay, or if it is required to repay the grant funds only if the research and development activities are successful, then the
grant agreement is accounted for as a contract to perform research and development services for others, in which case, grant revenue
is recognized when the related research and development expenses are incurred (see Note 15).
Deferred
grant revenues represent grant funds received from the governmental funding agencies for which the allowable expenses have not
yet been incurred as of the balance sheet date reported. As of September 30, 2018, deferred grant revenue was immaterial.
Arrangements
with multiple performance obligations
. BioTime’s contracts with customers may include multiple performance obligations.
For such arrangements, BioTime allocates revenue to each performance obligation based on its relative standalone selling price.
BioTime generally determines or estimates standalone selling prices based on the prices charged, or that would be charged, to
customers for that product or service. As of, and for the nine months ended, September 30, 2018, BioTime did not have significant
arrangements with multiple performance obligations.
Adoption
of ASU 2016-01, Financial Instruments–Overall: Recognition and Measurement of Financial Assets and Financial Liabilities
.
Changes to the current GAAP model under ASU 2016-01 primarily affects the accounting for
equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial
instruments. In addition, ASU 2016-01 clarified guidance related to the valuation allowance assessment when recognizing deferred
tax assets resulting from unrealized losses on available-for-sale debt securities. The accounting for other financial instruments,
such as loans, investments in debt securities, and financial liabilities is largely unchanged. The more significant amendments
are to equity investments in unconsolidated entities. In accordance with ASU No. 2016-01, all equity investments in unconsolidated
entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through
earnings. There will no longer be an available-for-sale classification (changes in fair value reported in other comprehensive
income) for equity securities with readily determinable fair values.
As further discussed above under the
marketable
equity securities
policy, BioTime adopted ASU 2016-01 on January
1, 2018.
Recently
Issued Accounting Pronouncements Not Yet Adopted
– The recently issued accounting pronouncements applicable to BioTime
that are not yet effective should be read in conjunction with the recently issued accounting pronouncements, as applicable and
disclosed in BioTime’s Annual Report on Form 10-K, as amended, for the year ended December 31, 2017.
In
February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)”, which requires lessees to recognize assets and liabilities
for leases with lease terms greater than twelve months in the statement of financial position. Leases will be classified as either
finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU 2016-02 also
requires improved disclosures to help users of financial statements better understand the amount, timing and uncertainty of cash
flows arising from leases. The update is effective for fiscal years beginning after December 15, 2018, including interim reporting
periods within that reporting period. Early adoption is permitted. BioTime is evaluating the impact the adoption of ASU 2016-02
will have on its consolidated financial statements. BioTime expects that most of its operating lease commitments will be subject
to the new standard and recognized as right-of-use assets and operating lease liabilities upon the adoption of ASU 2016-02, which
will increase the total consolidated assets and total consolidated liabilities that it reports.
|
3.
|
Sale
of significant ownership interest in AgeX to Juvenescence Limited
|
On
August 30, 2018, BioTime entered into a Stock Purchase Agreement with Juvenescence Limited and AgeX Therapeutics, Inc., pursuant
to which BioTime sold 14.4 million shares of the common stock of AgeX to Juvenescence for $3.00 per share.
The
Purchase Agreement provides for a total purchase price for the AgeX Shares of $43.2 million (the “Purchase Price”),
of which $10.8 million was paid upon the closing of the Juvenescence Transaction and $10.8 million was paid on November 2, 2018
(see Note 16), with the remaining $21.6 million to be paid under the terms of an unsecured convertible promissory note (the “Promissory
Note”). Juvenescence’s obligation to pay the second installment of $10.8 million is secured by a pledge of 3.6 million
AgeX Shares (see Note 16).
The
Promissory Note, dated August 30, 2018, bears interest at 7% per annum, with principal and accrued interest payable at maturity
two years after the closing of the Juvenescence Transaction. The Promissory Note cannot be prepaid by Juvenescence prior to maturity
or conversion. On the maturity date, if a “Qualified Financing” (as defined below) has not occurred, BioTime shall
have the right, but not the obligation, to convert the principal balance of the Promissory Note and accrued interest then due
into a number of Series A Preferred Shares of Juvenescence at a conversion price of $15.60 per share. Upon the occurrence of a
“Qualified Financing” on or before the maturity date, the principal balance of the Promissory Note and accrued interest
on the Promissory Note will automatically convert into a number of shares of the class of equity securities of Juvenescence sold
in the Qualified Financing, at the price per share at which the Juvenescence securities are sold in the Qualified Financing; and,
if AgeX common stock is listed on a national securities exchange in the U.S., the number of shares of the class of equity securities
issuable upon conversion may be increased depending on the market price of AgeX common stock. A Qualified Financing means an underwritten
initial public offering of Juvenescence equity securities in which gross proceeds are not less than $50.0 million. The Promissory
Note is not transferable, except in connection with a change of control of BioTime. The Purchase Agreement contains customary
representations, warranties and indemnities from BioTime relating to the business of AgeX, including an indemnity cap of $4.3
million, which is subject to certain exceptions.
BioTime
has accounted for the Promissory Note as a financing receivable under ASC 310-10,
Receivables
, since it both represents
a contractual right to receive cash on a fixed date (at maturity on August 30, 2020) and is recognized as an asset on BioTime’s
consolidated balance sheet as part of the consideration received for the sale of the AgeX shares to Juvenescence. Under ASC 310-10,
the Promissory Note is issued at fair value on the Juvenescence Transaction date and subsequently carried at amortized cost with
accrued interest, subject to impairment testing under ASC 310.
For
the three and nine months ended September 30, 2018, BioTime recognized $0.1 million in interest income on the Promissory Note.
As of September 30, 2018, the Promissory Note principal and accrued interest balance was $21.7 million.
Shareholder
Agreement
As
provided in the Purchase Agreement, BioTime and Juvenescence entered into a Shareholder Agreement, dated August 30, 2018, setting
forth the governance, approval and voting rights of the parties with respect to their holdings of AgeX common stock, including
rights of representation on the AgeX Board of Directors, approval rights, preemptive rights, rights of first refusal and co-sale
and drag-along and tag-along rights for so long as either BioTime or Juvenescence continue to own at least 15% of the outstanding
shares of AgeX common stock. Pursuant to the Shareholder Agreement, Juvenescence and BioTime have the right to designate two persons
each to be appointed to the six member AgeX Board of Directors, with the remaining two individuals to be independent of Juvenescence
and BioTime. The number of authorized directors of AgeX has been increased to accommodate those appointments. Additionally, following
Juvenescence’s payment of the second cash installment on November 2, 2018, Juvenescence has the right to designate an additional
member of the AgeX Board of Directors. The size of the AgeX Board of Directors will be correspondingly increased.
In
connection with the Juvenescence Transaction, the termination provision of the Shared Facilities Agreement (see Note 11) entitling
AgeX or BioTime to terminate the agreement upon six months advance written notice was amended. Pursuant to the amendment, following
the deconsolidation of AgeX from BioTime’s consolidated financial statements on August 30, 2018 (see Notes 4 and 11), each
party retains the right to terminate the Shared Facilities Agreement at any time by giving the other party six months advance
written notice, but BioTime may not do so prior to September 1, 2020.
Following
the Juvenescence Transaction, BioTime continues to own 14.4 million shares of AgeX common stock (see Note 5) and Juvenescence
owns 16.4 million shares of AgeX common stock, which includes 2.0 million shares of AgeX common stock previously purchased from
AgeX in a private placement on June 7, 2018.
|
4.
|
Deconsolidation
of AgeX and OncoCyte
|
Deconsolidation
of AgeX
On
August 30, 2018, BioTime consummated the sale of AgeX Shares to Juvenescence (see Note 3). Prior to the Juvenescence Transaction,
Juvenescence owned 5.6% of AgeX’s issued and outstanding common stock. Upon completion of the Juvenescence Transaction,
BioTime’s ownership in AgeX decreased from 80.4% to 40.2% of AgeX’s issued and outstanding shares of common stock,
and Juvenescence’s ownership in AgeX increased from 5.6% to 45.8% of AgeX’s issued and outstanding shares of common
stock.
As
a result of the consummation of the Juvenescence Transaction on August 30, 2018, AgeX is no longer a subsidiary of BioTime and,
as of that date, BioTime experienced a “loss of control” of AgeX, as defined by GAAP.
Loss
of control is deemed to have occurred when, among other things, a parent company owns less than a majority of the outstanding
common stock of a subsidiary, lacks a controlling financial interest in the subsidiary, and is unable to unilaterally control
the subsidiary through other means such as having, or being able to obtain, the power to elect a majority of the subsidiary’s
Board of Directors based solely on contractual rights or ownership of shares representing a majority of the voting power of the
subsidiary’s voting securities. All of these loss-of-control factors were present with respect to BioTime’s ownership
interest in AgeX as of August 30, 2018.
Accordingly, BioTime has deconsolidated AgeX’s consolidated financial statements
and consolidated results from BioTime’s unaudited condensed consolidated financial statements and consolidated results effective
on August 30, 2018, in accordance with Accounting Standards Codification, or ASC, 810-10-40-4(c),
Consolidation
. AgeX is
currently an affiliate of BioTime.
In
connection with the Juvenescence Transaction discussed in Note 3 and the AgeX Deconsolidation on August 30, 2018, in accordance
with ASC 810-10-40-5, BioTime recorded a gain on deconsolidation of $78.5 million, which includes a financial reporting gain on
the sale of the AgeX shares of $39.2 million (see Note 14), during the three and nine months ended
September
30, 2018, included in other income and expenses, net, in the condensed consolidated statements of operations. See Note
5 for BioTime’s accounting of retained noncontrolling ownership interest in AgeX.
Deconsolidation
of OncoCyte
On
February 17, 2017, OncoCyte issued 625,000 shares of OncoCyte common stock to certain investors who exercised OncoCyte stock purchase
warrants. As a result of this exercise and the issuance of the shares of OncoCyte common stock, beginning on February 17, 2017,
BioTime owned less than 50% of the OncoCyte outstanding common stock and experienced a loss of control of the OncoCyte subsidiary
under GAAP. Accordingly, BioTime has deconsolidated OncoCyte’s financial statements and results of operations from BioTime,
effective February 17, 2017, in accordance with ASC, 810-10-40-4(c), referred to as the “OncoCyte Deconsolidation.”
Beginning
on February 17, 2017, BioTime is accounting for its retained noncontrolling investment in OncoCyte under the equity method of
accounting and has elected the fair value option under ASC 825-10 (see Note 6).
In
connection with the OncoCyte Deconsolidation and in accordance with ASC 810-10-40-5, BioTime recorded a gain on deconsolidation
of $71.7 million during the nine months ended
September
30, 2017, included in other
income and expenses, net, in the condensed consolidated statements of operations.
|
5.
|
Equity
Method Accounting for Common Stock of AgeX, at Fair Value
|
Beginning
on August
30
, 2018 and until the completion of the contemplated AgeX Distribution
(see Notes 1 and 16), BioTime will account for its retained noncontrolling interest of AgeX common stock under the equity method
of accounting because its 14,416,000 shares of AgeX common stock held, or 40.2% retained ownership interest provides BioTime
the
ability to exercise significant influence, but not control, over the operating and financial policies of AgeX
. BioTime
has elected to account for its AgeX shares at fair value under ASC 825-10,
Financial Instruments,
with subsequent changes
in the fair value of AgeX common stock recognized as gains or losses in its condensed consolidated statements of operations in
other income and expenses, net. If the planned AgeX Distribution is completed, BioTime will account for its retained AgeX shares
as marketable equity securities, at fair value (see Note 2).
Since
AgeX shares are not publicly traded, BioTime estimated the fair value of AgeX common stock held by BioTime to be $3.00 per share
as of September 30, 2018, unchanged from the Juvenescence Transaction price discussed in Note 3. This determination takes into
account the recent August 30, 2018 transaction, in which BioTime sold a 40.2% ownership interest in AgeX to Juvenescence for $3.00
per share, increasing Juvenescence’s direct ownership interest in AgeX to 45.8% as of August 30, 2018. The Juvenescence
Transaction purchase price of $43.2 million consisted of $21.6 million of cash and a short-term receivable (Notes 3 and 16), and
$21.6 million in the form of the Promissory Note (see Note 3) received in the Juvenescence Transaction. The terms of the Promissory
Note were negotiated terms by unrelated parties, and the interest rate of 7% approximates market terms, considering that BioTime
believes Juvenescence has the financial resources to repay the Promissory Note, if not converted sooner, and the risk of default
is low. Accordingly, BioTime believes that the $21.6 million face amount of the Promissory Note issued at the close of the Juvenescence
Transaction was at fair value. When the fair value of the Promissory Note and the cash payments for the sale of the AgeX shares
are combined, the resulting purchase price is $3.00 per share.
BioTime
believes this price is consistent with the definition of fair value under ASC 820, which defines fair value as “the price
that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants
at the measurement date.” This price represents the most reliable input available under ASC 820, a Level 2 input. A Level
2 input includes “quoted prices for identical or similar assets or liabilities in markets that are not active, that is,
markets in which there are few transactions for the asset or liability.” A Level 1 input is not available for AgeX as it
is not publicly traded, and any other approach to estimating the value of AgeX would be less reliable because it would require
unobservable Level 3 inputs or comparison to transactions in similar assets or liabilities, rather than the identical asset or
liability in the Juvenescence Transaction. Furthermore, BioTime believes the Juvenescence Transaction meets the other factors
that define fair value under ASC 820, because it represents an orderly transaction that was negotiated between market participants
who had reasonable knowledge of the AgeX security for which they were transacting. This includes the impact to value of the planned
listing of the AgeX common stock as a publicly traded security. Finally, there have been no material changes in the financial
condition of AgeX or in its business and operations between the Juvenescence Transaction date, August 30, 2018, and the current
measurement date of September 30, 2018. Accordingly, BioTime believes $3.00 per share represents the fair value of AgeX common
stock at September 30, 2018, resulting in no change in fair value since the Juvenescence Transaction date.
AgeX’s
unaudited condensed consolidated results of operations for the three and nine months ended
September
30, 2018 and 2017 are summarized below (in thousands):
|
|
Three Months Ended
September 30,
(unaudited)
|
|
|
July 1,
2018 to
August 29,
2018
|
|
|
Nine Months Ended
September 30,
(unaudited)
|
|
|
January 1,
2018 to
August 29,
2018
|
|
|
|
2018
|
|
|
2017
|
|
|
(unaudited)
|
|
|
2018
|
|
|
2017
|
|
|
(unaudited)
|
|
Condensed Consolidated Statements of Operations
(1)
:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development expense
|
|
$
|
1,332
|
|
|
$
|
1,532
|
|
|
$
|
822
|
|
|
$
|
4,307
|
|
|
$
|
4,517
|
|
|
$
|
3,797
|
|
Acquired in-process research and development
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
800
|
|
|
|
-
|
|
|
|
800
|
|
General and administrative expense
|
|
|
1,254
|
|
|
|
722
|
|
|
|
770
|
|
|
|
3,679
|
|
|
|
3,174
|
|
|
|
3,130
|
|
Loss from operations
|
|
|
(2,202
|
)
|
|
|
(2,254
|
)
|
|
|
(1,473
|
)
|
|
|
(7,887
|
)
|
|
|
(5,105
|
)
|
|
|
(7,094
|
)
|
Net loss
|
|
$
|
(2,185
|
)
|
|
$
|
(2,011
|
)
|
|
$
|
(1.451
|
)
|
|
$
|
(4,457
|
)
|
|
$
|
(5,093
|
)
|
|
$
|
(3,688
|
)
|
(1)
The unaudited condensed consolidated statements of operations information included in the table above for the periods July
1, 2018 through August 29, 2018 and January 1, 2018 through August 29, 2018 reflects AgeX consolidated results of operations included
in BioTime’s condensed consolidated statements of operations for the three and nine months ended September 30, 2018, after
intercompany eliminations. The information for AgeX for the period from August 30, 2018 through September 30, 2018 is not included
in BioTime’s condensed consolidated statements of operations for the three months ended September 30, 2018. The information
for AgeX for the three and nine months ended September 30, 2017 is included in BioTime’s condensed consolidated statements
of operations for those periods.
|
6.
|
Equity
Method Accounting for Common Stock of OncoCyte, at Fair Value
|
BioTime
elected to account for its
14.7 million shares of OncoCyte common stock
at fair value
using the equity method of accounting beginning on February 17, 2017, the date of the OncoCyte Deconsolidation. The OncoCyte shares
had a fair value of $36.7 million as of
September
30, 2018 and a fair value of $
68.2
million as of December 31, 2017
, based on the closing price of OncoCyte of $2.50 per share and $
4.65
per share on those respective dates.
For
the three months ended
September
30, 2018, BioTime recorded an unrealized loss of
$0.7 million due to the decrease in OncoCyte’s stock price from June 30, 2018 to
September
30, 2018, from $2.55 per share to $2.50 per share
. For the nine months ended September
30, 2018, BioTime recorded an unrealized loss of $31.6 million on the OncoCyte shares due to the decrease in OncoCyte’s
stock price from December 31, 2017 to September 30, 2018 noted above.
For
the three months ended September 30, 2017, BioTime recorded an unrealized gain of $34.5 million due to the increase in OncoCyte’s
stock price from June 30, 2017 to September 30, 2017 from $5.20 per share to $7.55 per share. For the nine months ended September
30, 2017, BioTime recorded an unrealized gain of $39.6 million on the OncoCyte shares due to the increase in OncoCyte’s
stock price from February 17, 2017 to September 30, 2017 from $4.85 per share to $7.55 per share.
All
share prices are
determined based on
the closing price of OncoCyte common stock on
the NYSE American on the applicable dates.
OncoCyte’s
unaudited condensed results of operations for the three and nine months ended
September
30, 2018 and 2017 are summarized below (in thousands):
|
|
Three Months Ended September 30,
(unaudited)
|
|
|
Nine Months Ended September 30,
(unaudited)
|
|
|
January 1,
2017 to
February 16,
2017
|
|
|
|
2018
|
|
|
2017
|
|
|
2018
|
|
|
2017
|
|
|
(unaudited)
|
|
Condensed Statements of Operations
(1)
:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development expense
|
|
$
|
1,527
|
|
|
$
|
1,836
|
|
|
$
|
5,310
|
|
|
$
|
5,667
|
|
|
$
|
798
|
|
General and administrative expense
|
|
|
1,312
|
|
|
|
4,289
|
|
|
|
4,434
|
|
|
|
7,447
|
|
|
|
377
|
|
Sales and marketing expense
|
|
|
184
|
|
|
|
710
|
|
|
|
1,411
|
|
|
|
1,843
|
|
|
|
213
|
|
Loss from operations
|
|
|
(3,023
|
)
|
|
|
(6,835
|
)
|
|
|
(11,155
|
)
|
|
|
(14,957
|
)
|
|
|
(1,388
|
)
|
Net loss
|
|
$
|
(2,971
|
)
|
|
$
|
(6,906
|
)
|
|
$
|
(11,254
|
)
|
|
$
|
(15,415
|
)
|
|
$
|
(1,392
|
)
|
(1)
The unaudited condensed statements of operations information included in the table above for the period January 1, 2017
through February 16, 2017 reflects OncoCyte results of operations included in BioTime’s unaudited condensed consolidated
statement of operations for the nine months ended September 30, 2017, after intercompany eliminations. The information for OncoCyte
shown for three and nine months ended September 30, 2018, and for the three months ended September 30, 2017, is not included in
BioTime’s condensed consolidated statements of operations for those periods.
|
7.
|
Equity
Method Accounting for Common Stock of Asterias, at Fair Value
|
BioTime
elected to account for its
21.7 million shares of Asterias common stock
at fair value
using the equity method of accounting beginning on May 13, 2016, the date of the Asterias Deconsolidation. The Asterias shares
had a fair value of $28.3 million as of
September
30, 2018 and a fair value of $48.9
million as of December 31, 2017, based on the closing prices of Asterias common stock of $1.30 per share and $2.25 per share on
those respective dates. As of September 30, 2018, BioTime owns approximately 39% of the issued and outstanding common stock of
Asterias. See Note 16 for the definitive merger agreement entered into by BioTime and Asterias on November 7, 2018, for BioTime
to acquire the remaining ownership interest in Asterias.
For
the three months ended
September
30, 2018, BioTime recorded an unrealized loss of
$1.1 million on the Asterias shares due to the decrease in Asterias’ stock price from June 30, 2018 to
September
30, 2018 from $1.35 per share to $1.30 per share. For the nine months ended
September
30, 2018, BioTime recorded an unrealized loss
of $
20.7 million
on
the Asterias shares due to the decrease
in Asterias’ stock price from December 31, 2017 to
September
30, 2018 noted above.
For
the three months ended
September
30, 2017, BioTime recorded an unrealized loss of
$3.3 million on the Asterias shares due to the decrease in Asterias’ stock price from June 30, 2017 to
September
30, 2017 from $3.55 per share to $3.40 per share. For the nine months ended
September
30, 2017, BioTime recorded an unrealized loss of $26.1 million on the Asterias shares due to the decrease in Asterias’
stock price from December 31, 2016 to
September
30, 2017 from $4.60 per share to
$3.40 per share.
All
share prices
are determined based on
the closing price of Asterias common stock on
the NYSE American on the applicable dates.
Asterias’
unaudited condensed results of operations for the three and nine months ended
September
30, 2018 and 2017 are summarized below (in thousands):
|
|
Three Months Ended
September 30,
(unaudited)
|
|
|
Nine Months Ended
September 30,
(unaudited)
|
|
|
|
2018
|
|
|
2017
|
|
|
2018
|
|
|
2017
|
|
Condensed Statements of Operations
(1):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue
|
|
$
|
116
|
|
|
$
|
1,688
|
|
|
$
|
703
|
|
|
$
|
4,014
|
|
Gross profit
|
|
|
59
|
|
|
|
1,607
|
|
|
|
526
|
|
|
|
3,863
|
|
Loss from operations
|
|
|
(5,361
|
)
|
|
|
(7,063
|
)
|
|
|
(16,036
|
)
|
|
|
(24,703
|
)
|
Net loss
|
|
$
|
(4,454
|
)
|
|
$
|
(6,809
|
)
|
|
$
|
(13,748
|
)
|
|
$
|
(21,824
|
)
|
(1)
The condensed unaudited statements of operations information included in the table above reflects Asterias’ results
of operations and were not included in BioTime’s condensed consolidated statements of operations.
|
8.
|
Property,
Plant and Equipment, Net
|
At
September
30, 2018 and December 31, 2017, property, plant and equipment was comprised
of the following (in thousands):
|
|
September 30, 2018
(unaudited)
|
|
|
December 31, 2017
|
|
Equipment, furniture and fixtures
|
|
$
|
4,107
|
|
|
$
|
4,255
|
|
Leasehold improvements
|
|
|
3,544
|
|
|
|
4,434
|
|
Accumulated depreciation and amortization
|
|
|
(2,962
|
)
|
|
|
(3,156
|
)
|
Property, plant and equipment, net
|
|
|
4,689
|
|
|
|
5,533
|
|
Leasehold improvements construction in progress (Note 15)
|
|
|
428
|
|
|
|
-
|
|
Property, plant and equipment, net, including construction in progress
|
|
$
|
5,117
|
|
|
$
|
5,533
|
|
Depreciation
expense, including amortization of leasehold improvements, amounted to $254,000 and $249,000 for the three months ended
September
30, 2018 and 2017, and $814,000 and $670,000 for the nine months ended
September
30, 2018 and 2017, respectively. During the nine months ended
September
30,
2018, BioTime wrote off $0.7 million in fully depreciated property and equipment with a corresponding adjustment to accumulated
depreciation and amortization.
Leasehold
improvements construction in progress is not depreciated until the asset is placed into service.
|
9.
|
Intangible
Assets, Net
|
At
September
30, 2018 and December 31, 2017, intangible assets,
primarily
consisting of acquired patents, and accumulated amortization were as follows (in thousands):
|
|
September 30, 2018
(unaudited)
(1)
|
|
|
December 31, 2017
|
|
Intangible assets
|
|
$
|
19,020
|
|
|
$
|
23,294
|
|
Accumulated amortization
|
|
|
(15,420
|
)
|
|
|
(16,394
|
)
|
Intangible assets, net
|
|
$
|
3,600
|
|
|
$
|
6,900
|
|
BioTime
recognized in research and development expenses $0.6 million and $1.8 million of amortization expense in each of the three month
and nine months ended
September
30, 2018 and 2017, respectively.
(1)
Reflects the effect of the AgeX Deconsolidation.
|
10.
|
Accounts
Payable and Accrued Liabilities
|
At
September
30, 2018 and December 31, 2017, accounts payable and accrued liabilities
consisted of the following (in thousands):
|
|
September 30, 2018
(unaudited)
(1)
|
|
|
December 31, 2017
|
|
Accounts payable
|
|
$
|
717
|
|
|
$
|
938
|
|
Accrued compensation
|
|
|
1,971
|
|
|
|
2,275
|
|
Accrued liabilities
|
|
|
1,394
|
|
|
|
2,505
|
|
Total
|
|
$
|
4,082
|
|
|
$
|
5,718
|
|
(1)
Reflects the effect of the AgeX Deconsolidation.
|
11.
|
Related
Party Transactions
|
Shared
Facilities and Service Agreements with Affiliates
The
receivables from affiliates shown on the condensed consolidated balance sheet as of
September
30, 2018 and December 31, 2017, primarily represent amounts owed to BioTime by OncoCyte and AgeX under certain Shared Facilities
and Service Agreements (each a “Shared Facilities Agreement”), with amounts owed by OncoCyte comprising most of that
amount. Under the terms of the Shared Facilities Agreements, BioTime allows OncoCyte and AgeX to use BioTime’s premises
and equipment located at BioTime’s headquarters in Alameda, California for the purpose of conducting business. BioTime also
provides accounting, billing, bookkeeping, payroll, treasury, payment of accounts payable, and other similar administrative services
to OncoCyte and AgeX. BioTime may also provide the services of attorneys, accountants, and other professionals who may provide
professional services to BioTime and its other subsidiaries. BioTime also has provided OncoCyte and AgeX with the services of
laboratory and research personnel, including BioTime employees and contractors, for the performance of research and development
work for OncoCyte and AgeX at the premises.
BioTime
charges OncoCyte and AgeX a “Use Fee” for services provided and usage of BioTime facilities, equipment, and supplies.
For each billing period, BioTime prorates and allocates to OncoCyte and AgeX costs incurred, including costs for services of BioTime
employees and use of equipment, insurance, leased space, professional services, software licenses, supplies and utilities. The
allocation of costs depends on key cost drivers, including actual documented use, square footage of facilities used, time spent,
costs incurred by BioTime for OncoCyte and AgeX, or upon proportionate usage by BioTime, OncoCyte and AgeX, as reasonably estimated
by BioTime. BioTime, at its discretion, has the right to charge OncoCyte and AgeX a 5% markup on such allocated costs. The allocated
cost of BioTime employees and contractors who provide services is based upon the number of hours or estimated percentage of efforts
of such personnel devoted to the performance of services.
The
Use Fee is determined and invoiced to OncoCyte and AgeX on a regular basis, generally monthly or quarterly. If the Shared Facilities
Agreement terminates prior to the last day of a billing period, the Use Fee will be determined for the number of days in the billing
period elapsed prior to the termination of the Shared Facilities Agreement. Each invoice is payable in full within 30 days after
receipt. Any invoice, or portion thereof, not paid in full when due will bear interest at the rate of 15% per annum until paid,
unless the failure to make a payment is due to any inaction or delay in making a payment by BioTime. Through
September
30, 2018, BioTime has not charged OncoCyte or AgeX any interest.
In
addition to the Use Fees, OncoCyte or AgeX will reimburse BioTime for any out of pocket costs incurred by BioTime for the purchase
of office supplies, laboratory supplies, and other goods and materials and services for the account or use of OncoCyte, provided
that invoices documenting such costs are delivered to OncoCyte or AgeX with each invoice for the Use Fee. BioTime will have no
obligation to purchase or acquire any office supplies or other goods and materials or any services for OncoCyte or AgeX, and if
any such supplies, goods, materials or services are obtained for OncoCyte or AgeX, BioTime may arrange for the suppliers to invoice
OncoCyte or AgeX directly.
Either
Shared Facilities Agreement will remain in effect unless a party gives the other party written notice stating that the Shared
Facilities Agreement will terminate on December 31 of that year, or unless the agreement is otherwise terminated under another
provision of the agreement. BioTime and AgeX may each terminate their Shared Facilities Agreement prior to December 31 of the
year by giving the other party written six months’ notice to terminate, but BioTime may not do so prior to September 1,
2020.
In
the aggregate, BioTime charged Use Fees to OncoCyte and AgeX as follows (in thousands):
|
|
Three Months Ended
September 30,
(unaudited)
|
|
|
Nine Months Ended
September 30,
(unaudited)
|
|
|
|
2018
|
|
|
2017
|
|
|
2018
|
|
|
2017
|
|
Research and development
|
|
$
|
355
|
|
|
$
|
229
|
|
|
$
|
792
|
|
|
$
|
859
|
|
General and administrative
|
|
|
187
|
|
|
|
161
|
|
|
|
533
|
|
|
|
318
|
|
Total use fees
|
|
$
|
542
|
|
|
|
390
|
|
|
|
1,325
|
|
|
|
1,177
|
|
The
Use Fees charged to OncoCyte and AgeX shown above are not reflected in revenues, but instead BioTime’s general and administrative
expenses and research and development expenses are shown net of those charges in the condensed consolidated statements of operations.
As of
September
30, 2018 and December 31, 2017, BioTime has a $2.1 million receivable
from OncoCyte included in receivable from affiliates, net, on account of Use Fees incurred by OncoCyte under the Shared Facilities
Agreement. As of
September
30, 2018, BioTime has a $0.1 million receivable from AgeX
included in receivable from affiliates, net, on account of Use Fees incurred by AgeX, while amounts owed to BioTime as of December
31, 2017 were eliminated in consolidation with BioTime as of that date. Since these amounts are due and payable within 30 days
of being invoiced, the receivable is classified as a current asset.
BioTime
accounts for receivables from affiliates, net of payables to affiliates, if any, for similar shared services and other transactions
BioTime’s consolidated subsidiaries may enter into with nonconsolidated affiliates. BioTime and the affiliates record those
receivables and payables on a net basis since BioTime and the affiliates intend to exercise a right of offset of the receivable
and the payable and to settle the balances net by having the party that owes the other party pay the net balance owed.
Transactions
with Ascendance Biotechnology, Inc.
On
March 21, 2018, AgeX and Ascendance Biotechnology, Inc. (“Ascendance”), an equity method investee of AgeX and former
equity method investee of BioTime, entered into an Asset Purchase Agreement (the “Asset Agreement”) in which AgeX
purchased for $800,000 in cash certain assets consisting primarily of in-process research and development assets related to stem
cell derived cardiomyocytes (heart muscle cells) to be developed by AgeX. The transaction was considered an asset acquisition
rather than a business combination in accordance with ASC 805-50,
Business Combinations
. Accordingly, the $800,000 purchase
price was expensed on the acquisition date as acquired in-process research and development as those assets have no alternative
future use. Also, on March 21, 2018, BioTime received $0.2 million from Ascendance as settlement of its accounts receivable from
Ascendance.
Disposition
of ownership interest in Ascendance
On
March 23, 2018, Ascendance was acquired by a third party in a merger through which AgeX received approximately $3.2 million in
cash for its shares of Ascendance common stock. AgeX recognized a $3.2 million gain on the sale of its equity method investment
in Ascendance, which is included in other income and expenses, net, for the nine months ended September 30, 2018.
Other
related party transactions
In
February 2018,
Alfred D. Kingsley, the Chairman of BioTime’s Board of Directors and
a former officer and director of AgeX,
purchased AgeX stock purchase warrants entitling him to purchase 248,600 shares
of AgeX common stock at an exercise price of $2.50 per share. AgeX received $124,300, or $0.50 per warrant, from Mr. Kingsley.
The warrants were sold to Mr. Kingsley on the same terms as other warrants were sold by AgeX to other unaffiliated investors.
BioTime
currently pays $5,050 per month for the use of approximately 900 square feet of office space in New York City, which is made available
to BioTime on a month-by-month basis by one of its directors at an amount that approximates his cost.
Preferred
Shares
BioTime
is authorized to issue 2,000,000 preferred shares. The preferred shares may be issued in one or more series as the board of directors
may determine by resolution. The board of directors is authorized to fix the number of shares of any series of preferred shares
and to determine or alter the rights, preferences, privileges, and restrictions granted to or imposed on the preferred shares
as a class, or upon any wholly unissued series of any preferred shares. The board of directors may, by resolution, increase or
decrease (but not below the number of shares of such series then outstanding) the number of shares of any series of preferred
shares subsequent to the issue of shares of that series. There are no preferred shares issued and outstanding.
Common
Shares
At
September 30, 2018, BioTime was authorized to issue 250,000,000 common shares, no par value. As of
September
30, 2018, and December 31, 2017, BioTime had 126,884,470 and 126,865,634 issued and outstanding common shares, respectively.
On
April 6, 2017, BioTime, entered into a Controlled Equity Offering
SM
Sales Agreement (the “Sales Agreement”)
with Cantor Fitzgerald & Co., as sales agent (“Cantor Fitzgerald”), pursuant to which BioTime may offer and sell,
from time to time, through Cantor Fitzgerald, shares of BioTime common stock, no par value, having an aggregate offering price
of up to $25,000,000. BioTime is not obligated to sell any shares under the Sales Agreement. Subject to the terms and conditions
of the Sales Agreement, Cantor Fitzgerald will use commercially reasonable efforts, consistent with its normal trading and sales
practices, applicable state and federal law, rules and regulations, and the rules of the NYSE American, to sell the shares from
time to time based upon BioTime’s instructions, including any price, time or size limits specified by BioTime. Under the
Sales Agreement, Cantor Fitzgerald may sell the shares by any method deemed to be an “at-the-market” offering as defined
in Rule 415(a)(4) under the Securities Act of 1933, as amended, or by any other method permitted by law, including in privately
negotiated transactions. Cantor Fitzgerald’s obligations to sell the shares under the Sales Agreement are subject to satisfaction
of certain conditions, including the continued effectiveness of BioTime’s Registration Statement on Form S-3 which became
effective on May 5, 2017. As of
September
30, 2018, $24.2 million remained available
for sale through the Sales Agreement under the Registration Statement.
BioTime
will pay Cantor Fitzgerald a commission of 3.0% of the aggregate gross proceeds from each sale of shares, reimburse legal fees
and disbursements and provide Cantor Fitzgerald with customary indemnification and contribution rights. The Sales Agreement may
be terminated by Cantor Fitzgerald or BioTime at any time upon notice to the other party, or by Cantor Fitzgerald at any time
in certain circumstances, including the occurrence of a material and adverse change in BioTime’s business or financial condition
that makes it impractical or inadvisable to market the shares or to enforce contracts for the sale of the shares.
Transactions
with Noncontrolling Interests of AgeX Therapeutics, Inc.
AgeX
was formed by BioTime to continue the development of BioTime’s technology relating to cell immortality and regenerative
biology by developing products for the treatment of aging and age-related diseases. On August 17, 2017, AgeX received its initial
assets and cash from BioTime and certain outside investors. BioTime contributed certain assets and cash to AgeX in exchange for
28,800,000 shares of AgeX common stock pursuant to an Asset Contribution and Separation Agreement (the “Asset Contribution
Agreement”). BioTime and AgeX also entered into a License Agreement pursuant to which BioTime licensed or sublicensed to
AgeX, and AgeX granted to BioTime an option to license back, certain patent rights. Concurrently with the acquisition of assets
from BioTime under the Asset Contribution Agreement, AgeX sold 4,950,000 shares of its common stock for $10.0 million in cash
primarily to outside investors, which included the Chairman of BioTime’s Board of Directors who was also an officer and
director of AgeX. At the close of the financing on August 17, 2017, BioTime owned 85.4% of the issued and outstanding shares of
AgeX common stock.
On
June 7, 2018, AgeX sold 2.0 million shares of common stock to Juvenescence for $2.50 per share for aggregate cash proceeds to
AgeX of $5.0 million. As of the completion of this financing on June 7, 2018, BioTime owned 80.6% of the
issued
and outstanding shares of AgeX common stock and retained a controlling interest in AgeX.
On
August 30, 2018, BioTime sold a significant ownership interest in AgeX to Juvenescence and currently owns 40.2% of the issued
and outstanding shares of AgeX common stock, resulting in the AgeX Deconsolidation on that date (see Notes 4 and 5).
Cell
Cure Warrants – Liability Classified
On
July 10, 2017, BioTime purchased all of the outstanding Cell Cure convertible promissory notes and Cell Cure ordinary shares held
by
Hadasit
Bio-Holdings, Ltd. (“HBL”)
,
a former Cell Cure shareholder that owned 21.2% of the issued and outstanding Cell Cure ordinary shares and substantially all
of the Cell Cure convertible promissory notes issued by Cell Cure to shareholders other than BioTime
. As an inducement
to HBL to sell its Cell Cure ordinary shares to BioTime, Cell Cure issued 24,566 warrants to HBL (the “HBL Warrants”)
to purchase Cell Cure ordinary shares at an exercise price of $40.5359 per warrant share, payable in U.S. dollars. The exercise
price of the HBL Warrants is the same price per ordinary share paid by BioTime to HBL for the purchase of the Cell Cure ordinary
shares held by HBL. The HBL Warrants are immediately exercisable and expire on the earliest to occur of 5 years from the issuance
date or immediately prior to the closing of a Corporate Transaction or an initial public offering, as such terms are defined in
the HBL Warrant Agreement.
Cell
Cure also has issued 13,738 warrants to purchase Cell Cure ordinary shares at exercise prices ranging from $32.02 to $40.00 per
warrant share, payable in U.S. dollars, to consultants (the “Consultant Warrants”), expiring in October 2020 and January
2024. The HBL Warrants and the Consultant Warrants are collectively referred to as the “Cell Cure Warrants”.
Because
the exercise price of the Cell Cure Warrants is U.S. dollar-denominated and settlement is not expected to occur in the next twelve
months, Cell Cure classified the Cell Cure Warrants as a long-term liability in accordance with ASC 815,
Derivatives and Hedging
.
ASC 815 requires freestanding financial instruments, such as warrants, with exercise prices denominated in currencies other than
the functional currency of the issuer to be accounted for as liabilities at fair value, with all subsequent changes in fair value
after the issuance date to be recorded as gains or losses in the consolidated statements of operations.
The
fair value of the Cell Cure Warrants at the time of issuance was determined by using the Black-Scholes option pricing model using
the respective contractual term of the warrants. In applying this model, the fair value is determined by applying Level 3 inputs,
as defined by ASC 820; these inputs are based on certain key assumptions including the fair value of the Cell Cure ordinary shares,
adjusted for lack of marketability, as appropriate, and the expected stock price volatility over the term of the Cell Cure Warrants.
The fair value of the Cell Cure ordinary shares is determined by Cell Cure’s Board of Directors, which may engage a valuation
specialist to assist it in estimating the fair value, or may use recent transactions in Cell Cure shares, if any, as a reasonable
approximation of fair value, or may apply other reasonable methods to determining the fair value, including a discount for lack
of marketability. BioTime determines the stock price volatility using historical prices of comparable public company common stock
for a period equal to the remaining term of the Cell Cure Warrants. The Cell Cure Warrants are revalued each reporting period
using the same methodology described above, with changes in fair value included as gains or losses in other income and expenses,
net, in the consolidated statements of operations. Changes in any of the key assumptions used to value the Cell Cure Warrants
could materially impact the fair value of the Cell Cure Warrants and BioTime’s consolidated financial statements.
For
the nine months ended
September
30, 2018, BioTime recorded a noncash gain of $0.4
million for the decrease in the fair value of the Cell Cure Warrants included in other income and expenses, net. For the three
months ended September 30, 2018, the change in the fair value of the Cell Cure Warrants was immaterial. The decrease in the fair
value of the Cell Cure Warrants was mainly attributable to the reduced remaining life of the warrants from the prior period, and
management’s assumption on the lack of marketability discount adjustment on the fair value of Cell Cure ordinary shares.
As of
September
30, 2018 and December 31, 2017, the Cell Cure Warrants, valued at
$0.4 million and $0.8 million, respectively, were included in long-term liabilities on the condensed consolidated balance sheets.
|
13.
|
Stock
Options and other Equity Awards
|
Equity
Incentive Plan Awards
BioTime
has adopted a 2012 Equity Incentive Plan (the “2012 Plan”), under which a maximum of 16,000,000 BioTime common shares
are available for the grant of stock options, restricted stock, restricted stock units and stock appreciation rights.
A
summary of BioTime’s 2012 Plan activity and other stock option awards granted outside of the 2012 Plan related information
is as follows (in thousands, except per share amounts):
|
|
Shares
Available
for Grant
|
|
|
Number
of Options
Outstanding
|
|
|
Number
of RSUs
Outstanding
|
|
|
Weighted
Average Exercise
Price of Options
|
|
December 31, 2017
(1)
|
|
|
2,485
|
|
|
|
8,043
|
|
|
|
62
|
|
|
$
|
3.38
|
|
Board mandated restriction restored
(1)
|
|
|
5,000
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Exchange of options with Cell Cure
(2)
|
|
|
(783
|
)
|
|
|
783
|
|
|
|
-
|
|
|
|
2.16
|
|
Options granted
|
|
|
(1,559
|
)
|
|
|
1,559
|
|
|
|
-
|
|
|
|
3.19
|
|
Options exercised
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Options forfeited/cancelled
|
|
|
427
|
|
|
|
(447
|
)
|
|
|
-
|
|
|
|
3.84
|
|
Restricted stock units granted
(3)
|
|
|
(1,586
|
)
|
|
|
-
|
|
|
|
793
|
|
|
|
-
|
|
Restricted stock units vested
(3)
|
|
|
-
|
|
|
|
-
|
|
|
|
(30
|
)
|
|
|
-
|
|
Inducement option grant
(4)
|
|
|
-
|
|
|
|
1,500
|
|
|
|
-
|
|
|
|
2.31
|
|
September 30, 2018
|
|
|
3,984
|
|
|
|
11,438
|
|
|
|
825
|
|
|
$
|
3.02
|
|
Options exercisable at September 30, 2018
|
|
|
|
|
|
|
5,959
|
|
|
|
|
|
|
$
|
3.32
|
|
(1)
On
October 13, 2017, BioTime’s Board of Directors (the “Board”) determined to temporarily set a 5.0 million total
share limit on shares available for the grant of share-based awards pursuant to the 2012 Plan. As of December 31, 2017, the total
2.5 million shares available for grant was net of this 5.0 million share restriction. On May 4, 2018, the Board removed this restriction,
thereby increasing shares available for the grant of share-based awards pursuant to the 2012 Plan.
(2)
On
July 9, 2018, the Board terminated the Cell Cure Equity Incentive Plan (the “Cell Cure Plan”), under which Cell Cure
employees and certain consultants (“Cell Cure Option Holders”) held outstanding options to purchase shares of common
stock in Cell Cure, and BioTime granted the Cell Cure Option Holders BioTime options of equivalent value under the 2012 Plan in
exchange for their Cell Cure options (the “BioTime Exchange”). The BioTime Exchange resulted in 783,000 grants of
BioTime stock options under the 2012 Plan, all issued with an exercise price of $2.16 per share to the Cell Cure Option Holders,
based on BioTime’s closing stock price on July 9, 2018. Of the total options granted under the BioTime Exchange, 257,000
are subject to continued service-based vesting from the original terms under the Cell Cure Plan, and 526,000 were immediately
vested on the exchange date to reflect the fact that the Cell Cure Options Holders held prior to the exchange were already vested.
Equivalent value of the BioTime Exchange was determined using the Black-Scholes option pricing model. The BioTime Exchange was
accounted for as a modification under ASC 718,
Compensation – Stock Compensation
, and BioTime recorded a noncash
stock-based compensation expense of $123,000 for the three and nine months ended September 30, 2018, included in the tables below.
(3)
On
May 24, 2018, BioTime granted 485,000 restricted stock units (“RSU”) to employees. The RSU will vest in increments
upon the attainment of specified performance conditions, as determined by the Board of Directors. Unvested RSUs will expire on
December 31, 2018. The conditions include the completion of the planned distribution of AgeX common stock to BioTime shareholders
and certain clinical milestones in the development of OpRegen
®
and Renevia
®
. Stock-based compensation
expense for these performance-based RSUs is recognized when it is probable that the respective milestone will be achieved, as
determined by the Board. As of
September
30, 2018, none of the RSU vesting conditions
were met and, accordingly, no stock-based compensation expense was recorded during the three and nine months ended
September
30, 2018. On October 4, 2018, the Board determined that BioTime had achieved the milestone of an AgeX performance-based
vesting event and as a result that 25%, or 121,250, of the RSUs granted on May 24, 2018 vested.
On
the September 17, 2018, BioTime granted BioTime’s new President and Chief Executive Officer, Brian M. Culley, an award of
200,000 restricted stock units (“RSU Award No. 1”) under the 2012 Plan. Subject to Mr. Culley’s continued service
with BioTime, 25% of the shares subject to RSU Award No. 1 will vest on the first anniversary of the date of grant, and the balance
of the shares subject to RSU Award No. 1 shall vest in 12 equal quarterly installments at the end of each quarter thereafter.
Additionally, BioTime granted Mr. Culley an award of 100,000 restricted stock units under the 2012 Plan (“RSU Award No.
2” and together with RSU Award No. 1, the “RSU Awards”). RSU Award No. 2 will vest fully on January 1, 2019,
subject to Mr. Culley’s continued service with BioTime.
(4)
On
September 17, 2018 (the “Start Date”), Brian M. Culley became President and Chief Executive Officer of BioTime. In
connection with Mr. Culley’s employment agreement BioTime granted Mr. Culley an inducement option to purchase 1,500,000
of BioTime’s common shares (the “Culley Option”). The exercise price of the Culley Option is $2.31 per share
based on BioTime’s closing stock price on September 17, 2018. This grant was made outside of the terms of the 2012 Plan
and was approved by the independent members of the Board of Directors. Subject to Mr. Culley’s continued service with BioTime
on the applicable vesting date, the Culley Option will vest and thereby become exercisable with respect to 25% of the shares on
the first anniversary of the Start Date, and the balance of the Culley Option will vest and become exercisable in 36 equal monthly
installments thereafter.
Stock-based
compensation expense
The
fair value of each option award is estimated on the date of grant using a Black-Scholes option pricing model applying the weighted-average
assumptions noted in the following table
:
|
|
Three Months Ended
September 30,
|
|
|
Nine Months Ended
September 30,
|
|
|
|
2018
|
|
|
2017
|
|
|
2018
|
|
|
2017
|
|
Expected life (in years)
|
|
|
5.55
|
|
|
|
3.88
|
|
|
|
5.68
|
|
|
|
5.47
|
|
Risk-free interest rates
|
|
|
2.86
|
%
|
|
|
1.65
|
%
|
|
|
2.77
|
%
|
|
|
1.78
|
%
|
Volatility
|
|
|
73.13
|
%
|
|
|
59.13
|
%
|
|
|
66.23
|
%
|
|
|
59.04
|
%
|
Dividend yield
|
|
|
-
|
%
|
|
|
-
|
%
|
|
|
-
|
%
|
|
|
-
|
%
|
Operating
expenses include stock-based compensation expense as follows (in thousands):
|
|
Three Months Ended
September 30,
(unaudited)
|
|
|
Nine Months Ended
September 30,
(unaudited)
|
|
|
|
2018
|
|
|
2017
|
|
|
2018
|
|
|
2017
|
|
Research and development
|
|
$
|
166
|
|
|
$
|
326
|
|
|
$
|
548
|
|
|
$
|
822
|
|
General and administrative
|
|
|
1,144
|
|
|
|
647
|
|
|
|
2,849
|
|
|
|
2,081
|
|
Total stock-based compensation expense
|
|
$
|
1,310
|
|
|
$
|
973
|
|
|
$
|
3,397
|
|
|
$
|
2,903
|
|
The
provision for income taxes for interim periods is determined using an estimated annual effective tax rate as prescribed by ASC
740-270,
Income Taxes, Interim Reporting
. The effective tax rate may be subject to fluctuations during the year as new
information is obtained, which may affect the assumptions used to estimate the annual effective tax rate, including factors such
as valuation allowances and changes in valuation allowances against deferred tax assets, the recognition or de-recognition of
tax benefits related to uncertain tax positions, if any, and changes in or the interpretation of tax laws in jurisdictions where
BioTime conducts business. ASC 740-270 also states that if an entity is unable to reliably estimate a part of its ordinary income
or loss, the income tax provision or benefit applicable to the item that cannot be estimated shall be reported in the interim
period in which the item is reported.
For
items that BioTime cannot reliably estimate on an annual basis (principally unrealized gains or losses generated by changes in
the market prices of the Asterias, OncoCyte, and AgeX shares BioTime holds), BioTime uses the actual year to date effective tax
rate rather than an estimated annual effective tax rate to determine the tax effect of each item, including the use of all available
net operating losses and other credits or deferred tax assets.
Although
the deconsolidation of Asterias and OncoCyte were not taxable transactions to BioTime and did not create a current income tax
payment obligation to BioTime, the market value of the shares of Asterias and OncoCyte common stock BioTime holds creates a deferred
tax liability to BioTime based on the closing prices of the shares, less BioTime’s tax basis in the shares. The deferred
tax liability generated by the Asterias and OncoCyte shares that BioTime holds as of
September
30, 2018, is a
source of future taxable income to BioTime, as prescribed by ASC 740-10-30-17,
that will more likely than not result in the realization of its deferred tax assets to the extent of the deferred tax liability.
This deferred tax liability is determined based on the closing prices of the Asterias and OncoCyte shares as of
September
30, 2018. Due to the inherent unpredictability of future prices of those shares, BioTime cannot reliably estimate or project
those deferred tax liabilities on an annual basis. Therefore, the deferred tax liability pertaining to Asterias and OncoCyte shares,
determined based on the actual closing prices on the last stock market trading day of the applicable accounting period, and the
related impacts to the valuation allowance and deferred tax asset changes, are recorded in the accounting period in which they
occur. The income tax consequences of the AgeX Deconsolidation are discussed below.
On
March 23, 2018, Ascendance was acquired by a third party in a merger through which AgeX received approximately $3.2 million in
cash for its shares of Ascendance common stock. For financial reporting purposes, AgeX recognized a $3.2 million gain as a sale
of its equity method investment in Ascendance (see Note 11).
The
sale was a taxable transaction to AgeX generating a taxable gain of approximately $2.2 million. BioTime has sufficient current
year losses from operations to offset the entire gain resulting in no income taxes due.
The
Juvenescence Transaction discussed in Note 3 was a taxable event for BioTime that resulted in a gross taxable gain of approximately
$30.8 million, which BioTime expects to be fully offset with available current year net operating losses (NOL) and NOL carryforwards,
resulting in no net income taxes due.
Although
the AgeX Deconsolidation on August 30, 2018 was not a taxable transaction to BioTime and did not result in a current tax payment
obligation, the unrealized financial reporting gain (see Note 4) on the AgeX Deconsolidation generated a deferred tax liability
in
accordance with ASC 740,
Income Taxes
, primarily representing BioTime’s
difference between book and tax basis of AgeX common stock on the AgeX Deconsolidation date. BioTime expects this deferred tax
liability to be fully offset by a corresponding release of BioTime’s valuation allowance on deferred tax assets, resulting
in no income tax provision or benefit from the AgeX Deconsolidation. The deferred tax liabilities on BioTime’s investments
in OncoCyte and Asterias, combined with the estimated deferred tax liability generated by the fair value of its retained noncontrolling
investment in AgeX, are considered to be sources of taxable income as prescribed by ASC 740-10-30-17 that will more likely than
not result in the realization of its deferred tax assets to the extent of those deferred tax liabilities, thereby reducing the
need for a valuation allowance.
A
valuation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized.
For federal and state income tax purposes, as a result of the deconsolidation of AgeX, Asterias and OncoCyte and the deferred
tax liabilities generated from the market values of AgeX, Asterias and OncoCyte shares from the respective deconsolidation dates,
including the changes to those deferred tax liabilities due to changes in the Asterias and OncoCyte stock prices, BioTime’s
deferred tax assets exceeded its deferred tax liabilities as of
September
30, 2018
and December 31, 2017. As a result, BioTime established a full valuation allowance as of
September
30, 2018 and December 31, 2017 due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards
and other deferred tax assets. Accordingly, BioTime did not record any provision or benefit for income taxes for the three and
nine months ended
September
30, 2018.
As
of September 30, 2017, BioTime’s deferred tax liabilities exceeded its deferred tax assets by $4.8 million. Accordingly,
as of September 30, 2017, for federal income tax purposes, BioTime released its entire valuation allowance and recognized a federal
deferred income tax expense of $4.8 million during the three and nine months ended September 30, 2017.
For
state income tax purposes, BioTime has a full valuation allowance on its state deferred tax assets for all periods presented and,
accordingly, no state tax provision or benefit was recorded for any period presented.
As
discussed in Note 16, t
he planned AgeX Distribution
will be a taxable event to BioTime. The amount of income tax obligation, if any, that BioTime may incur in connection with the
AgeX Distribution is not estimable at this time since the tax obligation depends on numerous factors and contingencies including,
but not limited to, the completion of the distribution, the amount and availability of U.S. net operating losses generated by
BioTime to offset any taxable gain as a result of the AgeX Distribution, and the value of AgeX common stock on the distribution
date.
See
Note 16 for the definitive merger agreement entered into by BioTime and Asterias on November 7, 2018, for BioTime to acquire the
remaining ownership interest in Asterias. If the merger is completed and is deemed to be a change of control, as defined by Internal
Revenue Code Section 382, utilization of the NOL and tax credit carryforwards may be subject to an annual limitation regarding
their utilization against Asterias’ taxable income in future periods.
|
15.
|
Commitments
and Contingencies
|
Alameda
Lease
On
December 10, 2015, BioTime entered into a lease for 30,795 square feet of office and laboratory space in two buildings located
in an office park in Alameda, California (the “Alameda Lease”). The term of the Alameda Lease is seven years and BioTime
has an option to renew the term for an additional five years. BioTime moved into the facility and the term of the Alameda Lease
commenced effective February 1, 2016.
Base
rent under the Alameda Lease on February 1, 2018 was $68,673 per month and will increase by approximately 3% annually on every
February 1 thereafter during the lease term. The lease payments allocated to the lease liability for leasehold improvements reimbursed
by the landlord are amortized as debt service on that liability over the lease term.
In
addition to base rent, BioTime will pay a pro rata portion of increases in certain expenses, including real property taxes, utilities
(to the extent not separately metered to the leased space) and the landlord’s operating expenses, over the amounts of those
expenses incurred by the landlord. As security for the performance of its obligations under the Alameda Lease, BioTime provided
the landlord with an initial security deposit of approximately $847,000, which was reduced by $423,000 on February 1, 2018 pursuant
to the lease agreement, and will be further reduced by an additional $346,000 after the first thirty-six months of the lease term,
by applying those amounts to future rent payment obligations under the lease, if BioTime is not in default under the Lease. The
security deposit amount under the Alameda Lease is considered restricted cash (see Note 2).
New
York Leased Office Space
BioTime
currently pays $5,050 per month for the use of approximately 900 square feet of office space in New York City, which is made available
to BioTime for use in conducting meetings and other business affairs, on a month-by-month basis, by one of its directors at an
amount that approximates his cost.
Cell
Cure Lease
Cell
Cure has leased 1,128 square meters (approximately 12,142 square feet) of office and laboratory space in Jerusalem, Israel under
a lease that expires between May 30, 2019 and December 31, 2020, with two additional options to extend the lease for 5 years each.
Base monthly rent is NIS 63,402 (approximately U.S. $18,247 per month). In addition to base rent, Cell Cure pays a pro rata share
of real property taxes and certain costs related to the operation and maintenance of the building in which the leased premises
are located.
On
January 28, 2018, Cell Cure entered into another lease agreement with its current landlord for an additional 934 square meters
(approximately 10,054 square feet) of office space in the same facility in Jerusalem, Israel under a lease that expires on December
31, 2025, with two additional options to extend the lease for 5 years each (the “January 2018 Lease”). The January
2018 Lease commenced on April 1, 2018, and includes a leasehold improvement construction allowance of up to NIS 4,000,000 (approximately
up to $1.2 million) from the landlord. The leasehold improvements are expected to be completed by December 31, 2018. Combined
base rent and construction allowance payments, assuming the full allowance is utilized, for the January 2018 Lease will be NIS
93,470 per month (approximately $27,000 per month) beginning on January 1, 2019.
During
the third quarter of 2018, Cell Cure made a $396,000 deposit required by the landlord under the January 2018 Lease included in
deposits and other long-term assets on the consolidated balance sheet as of September 30, 2018 to be held as restricted cash during
the term of the January 2018 Lease. As of
September
30, 2018, approximately $428,000
under the January 2018 Lease was incurred and recorded as leasehold improvement construction in progress (see Note 8), with a
corresponding $359,000 included in long term lease liability representing the amount utilized from the landlord’s
leasehold improvement construction allowance.
Litigation
– General
BioTime
will be subject to various claims and contingencies in the ordinary course of its business, including those related to litigation,
business transactions, employee-related matters, and others. When BioTime is aware of a claim or potential claim, it assesses
the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably
estimated, BioTime will record a liability for the loss. If the loss is not probable or the amount of the loss cannot be reasonably
estimated, BioTime will disclose the claim if the likelihood of a potential loss is reasonably possible and the amount involved
could be material. BioTime is not aware of any claims likely to have a material adverse effect on its financial condition or results
of operations.
Employment
contracts
BioTime
has entered into employment agreements with certain executive officers. Under the provisions of the agreements, BioTime may be
required to incur severance obligations for matters relating to changes in control, as defined in the agreements, and involuntary
terminations.
Indemnification
In
the normal course of business, BioTime may provide indemnifications of varying scope under BioTime’s agreements with other
companies or consultants, typically BioTime’s clinical research organizations, investigators, clinical sites, suppliers
and others. Pursuant to these agreements, BioTime will generally agree to indemnify, hold harmless, and reimburse the indemnified
parties for losses and expenses suffered or incurred by the indemnified parties arising from claims of third parties in connection
with the use or testing of BioTime’s products and services. Indemnification provisions could also cover third party infringement
claims with respect to patent rights, copyrights, or other intellectual property pertaining to BioTime products and services.
Other indemnification obligations may arise from agreements disposing of assets. The term of these indemnification agreements
will generally continue in effect after the termination or expiration of the particular research, development, services, or license
agreement to which they relate. The potential future payments BioTime could be required to make under these indemnification agreements
will generally not be subject to any specified maximum amount. Historically, BioTime has not been subject to any claims or demands
for indemnification. BioTime also maintains various liability insurance policies that limit BioTime’s financial exposure.
As a result, BioTime believes the fair value of these indemnification agreements is minimal. Accordingly, BioTime has not recorded
any liabilities for these agreements as of
September
30, 2018 and December 31, 2017.
Royalty
obligations and license fees
BioTime
and its subsidiaries or affiliates are parties to certain licensing agreements with research institutions, universities and other
parties for the rights to use those licenses and other intellectual property in conducting research and development activities.
These licensing agreements provide for the payment of royalties by BioTime or the applicable party to the agreement on future
product sales, if any. In addition, in order to maintain these licenses and other rights during the product development, BioTime
or the applicable party to the contract must comply with various conditions including the payment of patent related costs and
annual minimum maintenance fees. Annual minimum maintenance fees are approximately $135,000 to $150,000 per year. The research
and development risk for these products is significant. License fees and related expenses under these agreements were immaterial
for the periods presented in the condensed consolidated interim financial statements provided herein.
Grants
Under
the terms of a grant agreement between Cell Cure and
Israel Innovation Authority (“IIA”)
(formerly the Office of the Chief Scientist of Israel) of the Ministry of Economy and Industry, for the development of
OpRegen
®
,
Cell Cure will be required to pay royalties on future product sales, if any, up to the amounts received from the IIA, plus interest
indexed to LIBOR. Cell Cure’s research and product development activities under the grant are subject to substantial risks
and uncertainties and performed on a best efforts basis. As a result, Cell Cure is not required to make any payments under the
grant agreement unless it successfully commercializes
OpRegen
®
.
Accordingly,
pursuant to ASC 730-20, the Cell Cure grant is considered a contract to perform research and development services for others and
grant revenue will be recognized as the related research and development expenses are incurred (see Note 2).
Israeli
law pertaining to such government grants contain various conditions, including substantial penalties and restrictions on the transfer
of intellectual property, or the manufacture, or both, of products developed under the grant outside of Israel, as defined by
the IIA.
On
October 1, 2018, all 8,795,358 BioTime common share purchase warrants expired unexercised.
On
November 2, 2018, BioTime received the second installment of $10.8 million from the Juvenescence Transaction, and pursuant to
the Pledge Agreement, the pledged 3.6 million AgeX Shares were released to Juvenescence and the Pledge Agreement expired.
On
November 5, 2018, AgeX filed Amendment No. 4 to its Registration Statement on Form 10 with the SEC in connection with the planned
AgeX Distribution. If the AgeX Distribution is completed, BioTime shareholders of record on November 16, 2018 will receive one
share of AgeX common stock for every 10 BioTime common shares they own on November 28, 2018, the expected “Distribution
Date”. If the AgeX Distribution is completed, AgeX will become a public company and BioTime will continue to hold a minor
interest in AgeX common stock. The AgeX Distribution is subject to numerous conditions, including the SEC declaring AgeX’s
Registration Statement on Form 10 effective. There can be no assurance that the AgeX Distribution will be completed.
On
November 7, 2018, BioTime announced it entered into a definitive agreement to acquire the remaining ownership interest in Asterias
Biotherapeutics, Inc. in a stock-for-stock transaction pursuant to which Asterias shareholders will receive 0.71 shares of BioTime
common share for every share of Asterias common stock. As discussed in Note 7, BioTime currently owns approximately 39% of Asterias’
issued and outstanding common stock and accounts for Asterias as an equity method investment. If the merger is completed, Asterias
will cease to exist as a public company, BioTime will own all of the outstanding shares of Asterias’ common stock and consolidate
Asterias’ operations and results with its operations and consolidated results beginning on the consummation date of the
merger. Moreover, under specified circumstances, the merger agreement requires either party to pay the other a termination
fee of $2.0 million if the merger is not consummated or, under specified circumstances, an expense reimbursement of $1.5
million, which will be credited against the termination fee.
The
merger, the merger agreement and the transactions contemplated in the merger agreement have been unanimously recommended
by the special committee of the Asterias board and the special committee of the BioTime board and approved by the
respective board of directors of Asterias and BioTime (by unanimous vote of the respective disinterested members of the board
of directors of each company).
The acquisition is expected
to close in the first quarter of 2019, subject to approval by the shareholders of each of BioTime and Asterias and the
satisfaction of other customary closing conditions.